{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:46:47Z","timestamp":1792460807378,"version":"4.5.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40121-025-01243-x","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T08:34:48Z","timestamp":1761554088000},"page":"2853-2868","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Conceptual Methodological Framework for Incorporating Antimicrobial Resistance Considerations in Economic Models for Pneumococcal Conjugate Vaccines"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6209-4370","authenticated-orcid":false,"given":"Mark H.","family":"Rozenbaum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6088-451X","authenticated-orcid":false,"given":"Maria J.","family":"Tort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7535-997X","authenticated-orcid":false,"given":"Katherine K.","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desmond","family":"Dillon-Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5464-654X","authenticated-orcid":false,"given":"Benjamin M.","family":"Althouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Farkouh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"1243_CR1","doi-asserted-by":"crossref","unstructured":"Salam MA, Al-Amin MY, Salam MT, et al. Antimicrobial resistance: a growing serious threat for global public health. Healthcare (Basel). 2023;11(13):1946.","DOI":"10.3390\/healthcare11131946"},{"issue":"10325","key":"1243_CR2","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","volume":"399","author":"CJ Murray","year":"2022","unstructured":"Murray CJ, Ikuta KS, Sharara F, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629\u201355.","journal-title":"Lancet"},{"issue":"5","key":"1243_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0285170","volume":"18","author":"AN Poudel","year":"2023","unstructured":"Poudel AN, Zhu S, Cooper N, et al. The economic burden of antibiotic resistance: a systematic review and meta-analysis. PLoS ONE. 2023;18(5):e0285170.","journal-title":"PLoS ONE"},{"key":"1243_CR4","unstructured":"World Health Organization. Estimating the impact of vaccines in reducing antimicrobial resistance and antibiotic use: technical report. 2024. https:\/\/www.who.int\/publications\/i\/item\/9789240098787. Accessed Dec 9, 2024."},{"issue":"2","key":"1243_CR5","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1089\/vim.2017.0138","volume":"31","author":"AM Smith","year":"2018","unstructured":"Smith AM, Huber VC. The unexpected impact of vaccines on secondary bacterial infections following influenza. Viral Immunol. 2018;31(2):159\u201373.","journal-title":"Viral Immunol"},{"issue":"suppl_1","key":"1243_CR6","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1073\/pnas.0906078107","volume":"107","author":"BM Althouse","year":"2010","unstructured":"Althouse BM, Bergstrom TC, Bergstrom CT. A public choice framework for controlling transmissible and evolving diseases. Proc Natl Acad Sci. 2010;107(suppl_1):1696\u2013701.","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"1243_CR7","doi-asserted-by":"publisher","first-page":"e00428","DOI":"10.1128\/mBio.00428-16","volume":"7","author":"M Lipsitch","year":"2016","unstructured":"Lipsitch M, Siber GR. How can vaccines contribute to solving the antimicrobial resistance problem? MBio. 2016;7(3):e00428-e516.","journal-title":"MBio"},{"issue":"5","key":"1243_CR8","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41579-020-00506-3","volume":"19","author":"F Micoli","year":"2021","unstructured":"Micoli F, Bagnoli F, Rappuoli R, Serruto D. The role of vaccines in combatting antimicrobial resistance. Nat Rev Microbiol. 2021;19(5):287\u2013302.","journal-title":"Nat Rev Microbiol"},{"key":"1243_CR9","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.ijid.2019.10.005","volume":"90","author":"P Buchy","year":"2020","unstructured":"Buchy P, Ascioglu S, Buisson Y, et al. Impact of vaccines on antimicrobial resistance. Int J Infect Dis. 2020;90:188\u201396.","journal-title":"Int J Infect Dis"},{"key":"1243_CR10","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/14.4.801","author":"DM Musher","year":"1992","unstructured":"Musher DM. Infections caused by Streptococcus pneumoniae: clinical spectrum, pathogenesis, immunity, and treatment. Clin Infect Dis. 1992. https:\/\/doi.org\/10.1093\/clinids\/14.4.801.","journal-title":"Clin Infect Dis"},{"key":"1243_CR11","unstructured":"King L. Advisory Committee on Immunization Practices. Pediatric outpatient ARI visits and antibiotic us attributable to serotypes in higher valency PCVs. 2023. https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2023-02\/slides-02-22\/Pneumococcal-03-King-508.pdf. Accessed Mar 6, 2023."},{"key":"1243_CR12","unstructured":"World Health Organization. WHO bacterial priority pathogens list, 2024: Bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance. World Health Organization 2024. https:\/\/www.who.int\/publications\/i\/item\/9789240093461. Accessed Dec 12, 2024."},{"issue":"2","key":"1243_CR13","doi-asserted-by":"publisher","first-page":"e113","DOI":"10.1016\/S2666-5247(22)00303-2","volume":"4","author":"I Frost","year":"2023","unstructured":"Frost I, Sati H, Garcia-Vello P, et al. The role of bacterial vaccines in the fight against antimicrobial resistance: an analysis of the preclinical and clinical development pipeline. Lancet Microbe. 2023;4(2):e113\u201325.","journal-title":"Lancet Microbe"},{"issue":"49","key":"1243_CR14","doi-asserted-by":"publisher","first-page":"7479","DOI":"10.1016\/j.vaccine.2018.10.060","volume":"36","author":"JA Suaya","year":"2018","unstructured":"Suaya JA, Gessner BD, Fung S, et al. Acute otitis media, antimicrobial prescriptions, and medical expenses among children in the United States during 2011\u20132016. Vaccine. 2018;36(49):7479\u201386.","journal-title":"Vaccine"},{"issue":"14","key":"1243_CR15","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1056\/NEJMoa051642","volume":"354","author":"MH Kyaw","year":"2006","unstructured":"Kyaw MH, Lynfield R, Schaffner W, et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med. 2006;354(14):1455\u201363.","journal-title":"N Engl J Med"},{"issue":"3","key":"1243_CR16","doi-asserted-by":"publisher","first-page":"e00937","DOI":"10.1128\/mBio.00937-20","volume":"11","author":"F Ganaie","year":"2020","unstructured":"Ganaie F, Saad JS, McGee L, et al. A new pneumococcal capsule type, 10D, is the 100th serotype and has a large cps fragment from an oral streptococcus. MBio. 2020;11(3):e00937-e1020.","journal-title":"MBio"},{"issue":"1","key":"1243_CR17","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2023-063039","volume":"153","author":"I Yildirim","year":"2024","unstructured":"Yildirim I, Lapidot R, Shaik-Dasthagirisaheb YB, et al. Invasive pneumococcal disease after 2 decades of pneumococcal conjugate vaccine use. Pediatrics. 2024;153(1):e2023063039.","journal-title":"Pediatrics"},{"issue":"25","key":"1243_CR18","first-page":"521","volume":"62","author":"Centers for Disease Control and Prevention","year":"2013","unstructured":"Centers for Disease Control and Prevention. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6\u201318\u00a0years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2013;62(25):521\u20134.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"RR-11","key":"1243_CR19","first-page":"1","volume":"59","author":"JP Nuorti","year":"2010","unstructured":"Nuorti JP, Whitney CG, Centers for Disease Control and Prevention (CDC). Prevention of pneumococcal disease among infants and children-use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine-recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010;59(RR-11):1\u201318.","journal-title":"MMWR Recomm Rep"},{"issue":"3","key":"1243_CR20","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1093\/infdis\/jir755","volume":"205","author":"LM Hampton","year":"2012","unstructured":"Hampton LM, Farley MM, Schaffner W, et al. Prevention of antibiotic-nonsusceptible Streptococcus pneumoniae with conjugate vaccines. J Infect Dis. 2012;205(3):401\u201311.","journal-title":"J Infect Dis"},{"issue":"10","key":"1243_CR21","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1080\/14760584.2019.1676155","volume":"18","author":"M Tin Tin Htar","year":"2019","unstructured":"Tin Tin Htar M, van Den Biggelaar AH, Sings H, et al. The impact of routine childhood immunization with higher-valent pneumococcal conjugate vaccines on antimicrobial-resistant pneumococcal diseases and carriage: a systematic literature review. Expert Rev Vaccines. 2019;18(10):1069\u201389.","journal-title":"Expert Rev Vaccines"},{"key":"1243_CR22","unstructured":"Centers for Disease and Control Prevention. Outpatient Clinical Care for Pediatric Populations. 2024. https:\/\/www.cdc.gov\/antibiotic-use\/hcp\/clinical-care\/pediatric-outpatient.html. Accessed Sept 3, 2024."},{"issue":"1","key":"1243_CR23","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1001\/jamapediatrics.2013.3924","volume":"168","author":"T Marom","year":"2014","unstructured":"Marom T, Tan A, Wilkinson GS, Pierson KS, Freeman JL, Chonmaitree T. Trends in otitis media-related health care use in the United States, 2001\u20132011. JAMA Pediatr. 2014;168(1):68\u201375.","journal-title":"JAMA Pediatr"},{"key":"1243_CR24","unstructured":"Centers for Disease and Control Prevention. Antibiotic resistance threats in the United States, 2019. https:\/\/www.cdc.gov\/drugresistance\/pdf\/threats-report\/2019-ar-threats-report-508.pdf. Accessed Mar 6, 2023."},{"key":"1243_CR25","unstructured":"Pfizer. US FDA Approves PREVNAR 20\u00ae, Pfizer\u2019s 20-valent Pneumococcal Conjugate Vaccine for Infants and Children. 2023."},{"key":"1243_CR26","unstructured":"Centers for Disease and Control Prevention. Advisory Committee on Immunization Practices (ACIP) Recommendations. 2023 September 22. https:\/\/www.cdc.gov\/vaccines\/acip\/recommendations.html. Accessed Oct 9, 2023."},{"key":"1243_CR27","unstructured":"Centers for Disease and Control Prevention. Pneumococcal disease: Antibiotic-resistant Streptococcus pneumoniae. 2024 February 6. https:\/\/www.cdc.gov\/pneumococcal\/php\/drug-resistance\/index.html. Accessed Jul 3, 2024."},{"key":"1243_CR28","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiae142","author":"LM King","year":"2024","unstructured":"King LM, Andrejko KL, Kabbani S, et al. Outpatient visits and antibiotic use due to higher-valency pneumococcal vaccine serotypes. J Infect Dis. 2024. https:\/\/doi.org\/10.1093\/infdis\/jiae142.","journal-title":"J Infect Dis"},{"key":"1243_CR29","doi-asserted-by":"publisher","DOI":"10.1101\/2023.08.24.23294570","author":"LM King","year":"2023","unstructured":"King LM, Andrejko KL, Kabbani S, et al. Pediatric outpatient visits and antibiotic use attributable to higher valency pneumococcal conjugate vaccine serotypes. medRxiv. 2023. https:\/\/doi.org\/10.1101\/2023.08.24.23294570.","journal-title":"medRxiv"},{"key":"1243_CR30","unstructured":"Andrejko KL, Xue L, Webb A, et al. Antimicrobial non-susceptibility among invasive and non-invasive Streptococcus pneumoniae infections in the United States, 2018\u20132021. In: 13th Meeting of the International Society of Pneumonia & Pneumococcal Diseases; 2024; Cape Town, South Africa."},{"issue":"1","key":"1243_CR31","doi-asserted-by":"publisher","first-page":"e58","DOI":"10.1016\/S2214-109X(18)30422-4","volume":"7","author":"C Chen","year":"2019","unstructured":"Chen C, Cervero Liceras F, Flasche S, et al. Effect and cost-effectiveness of pneumococcal conjugate vaccination: a global modelling analysis. Lancet Glob Health. 2019;7(1):e58\u201367.","journal-title":"Lancet Glob Health"},{"issue":"4","key":"1243_CR32","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.inhe.2011.08.003","volume":"3","author":"A Tasslimi","year":"2011","unstructured":"Tasslimi A, Nakamura MM, Levine O, Knoll MD, Russell LB, Sinha A. Cost effectiveness of child pneumococcal conjugate vaccination in GAVI-eligible countries. Int Health. 2011;3(4):259\u201369.","journal-title":"Int Health"},{"issue":"3","key":"1243_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8030426","volume":"8","author":"N Zakiyah","year":"2020","unstructured":"Zakiyah N, Insani WN, Suwantika AA, van der Schans J, Postma MJ. Pneumococcal vaccination for children in asian countries: a systematic review of economic evaluation studies. Vaccines (Basel). 2020;8(3):426.","journal-title":"Vaccines (Basel)"},{"issue":"7","key":"1243_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0201245","volume":"13","author":"K Shen","year":"2018","unstructured":"Shen K, Wasserman M, Liu D, et al. Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in China. PLoS ONE. 2018;13(7):e0201245.","journal-title":"PLoS ONE"},{"issue":"3","key":"1243_CR35","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s10198-016-0770-9","volume":"18","author":"A Kuhlmann","year":"2017","unstructured":"Kuhlmann A, von der Schulenburg JG. Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany. Eur J Health Econ. 2017;18(3):273\u201392.","journal-title":"Eur J Health Econ"},{"key":"1243_CR36","doi-asserted-by":"crossref","unstructured":"Rozenbaum MH, Huang L, Cane A, et al. Cost-effectiveness and impact on infections and associated antimicrobial resistance of 20-valent pneumococcal conjugate vaccine in US children previously immunized with PCV13. J Med Econ. 2024;27(1):644\u201352.","DOI":"10.1080\/13696998.2024.2339638"},{"issue":"1","key":"1243_CR37","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12962-023-00458-4","volume":"21","author":"BM Malene","year":"2023","unstructured":"Malene BM, Oyvind H, Tor M, et al. Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting. Cost Effect Resour Alloc. 2023;21(1):52.","journal-title":"Cost Effect Resour Alloc"},{"issue":"2","key":"1243_CR38","doi-asserted-by":"publisher","first-page":"2257426","DOI":"10.1080\/21645515.2023.2257426","volume":"19","author":"D Lytle","year":"2023","unstructured":"Lytle D, Grajales Beltr\u00e1n AG, Perdrizet J, et al. Cost-effectiveness analysis of PCV20 to prevent pneumococcal disease in the Canadian pediatric population. Hum Vaccin Immunother. 2023;19(2):2257426.","journal-title":"Hum Vaccin Immunother"},{"key":"1243_CR39","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000002521","author":"DE Bloom","year":"2020","unstructured":"Bloom DE, Kirby PN, Pugh S, Stawasz A. Commentary: why has uptake of pneumococcal vaccines for children been so slow? The perils of undervaluation. Pediatr Infect Dis J. 2020. https:\/\/doi.org\/10.1097\/INF.0000000000002521.","journal-title":"Pediatr Infect Dis J"},{"issue":"10","key":"1243_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0186903","volume":"12","author":"ET Cafiero-Fonseca","year":"2017","unstructured":"Cafiero-Fonseca ET, Stawasz A, Johnson ST, Sato R, Bloom DE. The full benefits of adult pneumococcal vaccination: a systematic review. PLoS ONE. 2017;12(10):e0186903-e.","journal-title":"PLoS ONE"},{"issue":"6","key":"1243_CR41","doi-asserted-by":"publisher","first-page":"e204","DOI":"10.1016\/S1473-3099(17)30478-4","volume":"18","author":"KE Atkins","year":"2018","unstructured":"Atkins KE, Lafferty EI, Deeny SR, Davies NG, Robotham JV, Jit M. Use of mathematical modelling to assess the impact of vaccines on antibiotic resistance. Lancet Infect Dis. 2018;18(6):e204\u201313.","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"1243_CR42","doi-asserted-by":"publisher","first-page":"e01318","DOI":"10.1128\/JCM.01318-17","volume":"56","author":"CMC Rodrigues","year":"2018","unstructured":"Rodrigues CMC, Groves H. Community-acquired pneumonia in children: the challenges of microbiological diagnosis. J Clin Microbiol. 2018;56(3):e01318-e1417.","journal-title":"J Clin Microbiol"},{"key":"1243_CR43","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s41479-016-0005-y","volume":"8","author":"V Usonis","year":"2016","unstructured":"Usonis V, Ivaskevicius R, Diez-Domingo J, et al. Comparison between diagnosis and treatment of community-acquired pneumonia in children in various medical centres across Europe with the United States, United Kingdom and the World Health Organization guidelines. Pneumonia (Nathan). 2016;8:5.","journal-title":"Pneumonia (Nathan)"},{"key":"1243_CR44","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00623-19","author":"Q Li","year":"2019","unstructured":"Li Q, Cheng J, Wu Y, et al. Effects of delayed antibiotic therapy on outcomes in children with Streptococcus pneumoniae sepsis. Antimicrob Agents Chemother. 2019. https:\/\/doi.org\/10.1128\/aac.00623-19.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"1243_CR45","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/s41598-021-04349-7","volume":"12","author":"DP Eisen","year":"2022","unstructured":"Eisen DP, Hamilton E, Bodilsen J, et al. Longer than 2\u00a0hours to antibiotics is associated with doubling of mortality in a multinational community-acquired bacterial meningitis cohort. Sci Rep. 2022;12(1):672.","journal-title":"Sci Rep"},{"issue":"12","key":"1243_CR46","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1016\/j.jval.2022.09.066","volume":"25","author":"S Mohanty","year":"2022","unstructured":"Mohanty S, Johnson K, Watts J, Yu K, Gupta V. P54 antimicrobial resistance associated with worse outcomes in hospitalized adults with pneumococcal disease. Value Health. 2022;25(12):S13.","journal-title":"Value Health"},{"issue":"9","key":"1243_CR47","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1080\/21645515.2018.1476814","volume":"14","author":"KU Jansen","year":"2018","unstructured":"Jansen KU, Anderson AS. The role of vaccines in fighting antimicrobial resistance (AMR). Human Vaccines Immunotherap. 2018;14(9):2142\u20139.","journal-title":"Human Vaccines Immunotherap"},{"issue":"6","key":"1243_CR48","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1177\/2042098614554919","volume":"5","author":"C Llor","year":"2014","unstructured":"Llor C, Bjerrum L. Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem. Ther Adv Drug Saf. 2014;5(6):229\u201341.","journal-title":"Ther Adv Drug Saf"},{"key":"1243_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13756-018-0384-3","volume":"7","author":"P Shrestha","year":"2018","unstructured":"Shrestha P, Cooper BS, Coast J, et al. Enumerating the economic cost of antimicrobial resistance per antibiotic consumed to inform the evaluation of interventions affecting their use. Antimicrob Resist Infect Control. 2018;7:1\u20139.","journal-title":"Antimicrob Resist Infect Control"},{"issue":"1","key":"1243_CR50","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12955-021-01712-0","volume":"19","author":"T Koukoubani","year":"2021","unstructured":"Koukoubani T, Makris D, Daniil Z, et al. The role of antimicrobial resistance on long-term mortality and quality of life in critically ill patients: a prospective longitudinal 2-year study. Health Qual Life Outcomes. 2021;19(1):72.","journal-title":"Health Qual Life Outcomes"},{"key":"1243_CR51","doi-asserted-by":"publisher","first-page":"11387","DOI":"10.3389\/bjbs.2023.11387","volume":"80","author":"KWK Tang","year":"2023","unstructured":"Tang KWK, Millar BC, Moore JE. Antimicrobial resistance (AMR). Br J Biomed Sci. 2023;80:11387.","journal-title":"Br J Biomed Sci"},{"key":"1243_CR52","doi-asserted-by":"publisher","first-page":"5235","DOI":"10.2147\/IDR.S319780","volume":"14","author":"BD Menz","year":"2021","unstructured":"Menz BD, Charani E, Gordon DL, Leather AJM, Moonesinghe SR, Phillips CJ. Surgical antibiotic prophylaxis in an era of antibiotic resistance: common resistant bacteria and wider considerations for practice. Infect Drug Resist. 2021;14:5235\u201352.","journal-title":"Infect Drug Resist"},{"issue":"19, Supplement","key":"1243_CR53","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.vaccine.2024.06.017","volume":"42","author":"M Hasso-Agopsowicz","year":"2024","unstructured":"Hasso-Agopsowicz M, Sparrow E, Cameron AM, et al. The role of vaccines in reducing antimicrobial resistance: a review of potential impact of vaccines on AMR and insights across 16 vaccines and pathogens. Vaccine. 2024;42(19, Supplement 1):S1\u20138.","journal-title":"Vaccine"},{"key":"1243_CR54","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.mbs.2015.02.007","volume":"263","author":"D Gao","year":"2015","unstructured":"Gao D, Lietman TM, Porco TC. Antibiotic resistance as collateral damage: the tragedy of the commons in a two-disease setting. Math Biosci. 2015;263:121\u201332.","journal-title":"Math Biosci"},{"key":"1243_CR55","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1016\/j.cmi.2023.12.013","volume":"30","author":"R Kingston","year":"2024","unstructured":"Kingston R, Vella V, Pouwels KB, et al. Excess resource use and cost of drug-resistant infections for six key pathogens in Europe: a systematic review and Bayesian meta-analysis. Clin Microbiol Infect. 2024;30:S26\u201336.","journal-title":"Clin Microbiol Infect"},{"issue":"340","key":"1243_CR56","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c2509","volume":"2","author":"MH Rozenbaum","year":"2010","unstructured":"Rozenbaum MH, Sanders EA, van Hoek AJ, et al. Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines. BMJ. 2010;2(340):c2509.","journal-title":"BMJ"},{"issue":"1","key":"1243_CR57","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jinf.2011.10.015","volume":"64","author":"DR Strutton","year":"2012","unstructured":"Strutton DR, Farkouh RA, Earnshaw SR, et al. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and the Netherlands. J Infect. 2012;64(1):54\u201367.","journal-title":"J Infect"},{"issue":"28 Suppl 6","key":"1243_CR58","doi-asserted-by":"publisher","first-page":"G23","DOI":"10.1016\/j.vaccine.2010.06.016","volume":"19","author":"SE Talbird","year":"2010","unstructured":"Talbird SE, Taylor TN, Knoll S, Frostad CR, Garcia MS. Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries. Vaccine. 2010;19(28 Suppl 6):G23\u20139.","journal-title":"Vaccine"},{"key":"1243_CR59","doi-asserted-by":"crossref","unstructured":"Vo NX, Pham HL, Bui UM, Ho HT, Bui TT. Cost-effectiveness analysis of pneumococcal vaccines in the pediatric population: a systematic review. Healthcare (Basel). 2024;12(19):1950.","DOI":"10.3390\/healthcare12191950"},{"issue":"13","key":"1243_CR60","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2004933118","volume":"118","author":"E Lu","year":"2021","unstructured":"Lu E, Chen H-H, Zhao H, Ozawa S. Health and economic impact of the pneumococcal conjugate vaccine in hindering antimicrobial resistance in China. Proc Natl Acad Sci. 2021;118(13):e2004933118.","journal-title":"Proc Natl Acad Sci"},{"issue":"9","key":"1243_CR61","doi-asserted-by":"publisher","first-page":"e654","DOI":"10.1016\/S2468-2667(24)00161-0","volume":"9","author":"YH Choi","year":"2024","unstructured":"Choi YH, Bertran M, Litt DJ, Ladhani SN, Miller E. Potential impact of replacing the 13-valent pneumococcal conjugate vaccine with 15-valent or 20-valent pneumococcal conjugate vaccine in the 1+ 1 infant schedule in England: a modelling study. Lancet Public Health. 2024;9(9):e654\u201363.","journal-title":"Lancet Public Health"},{"key":"1243_CR62","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-025-01111-8","author":"RJ Oidtman","year":"2025","unstructured":"Oidtman RJ, Meleleo G, Sharomi O, et al. Modelling the epidemiological impact of different adult pneumococcal vaccination strategies in the United Kingdom. Infect Dis Ther. 2025. https:\/\/doi.org\/10.1007\/s40121-025-01111-8.","journal-title":"Infect Dis Ther"},{"issue":"4","key":"1243_CR63","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0305892","volume":"20","author":"TM Malik","year":"2025","unstructured":"Malik TM, Bakker KM, Oidtman RJ, et al. A dynamic transmission model for assessing the impact of pneumococcal vaccination in the United States. PLoS ONE. 2025;20(4):e0305892.","journal-title":"PLoS ONE"},{"issue":"6","key":"1243_CR64","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1080\/21645515.2020.1836918","volume":"17","author":"H Rinta-Kokko","year":"2021","unstructured":"Rinta-Kokko H, Nurhonen M, Auranen K. Impact and effectiveness of a conjugate vaccine against invasive pneumococcal disease in Finland-a modelling approach. Hum Vaccines Immunother. 2021;17(6):1834\u201343.","journal-title":"Hum Vaccines Immunother"},{"issue":"10","key":"1243_CR65","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1016\/j.cmi.2021.07.002","volume":"27","author":"A L\u00f8chen","year":"2021","unstructured":"L\u00f8chen A, Anderson RM. Dynamic transmission models and economic evaluations of pneumococcal conjugate vaccines: a quality appraisal and limitations. Clin Microbiol Infect. 2021;27(10):1546\u201357.","journal-title":"Clin Microbiol Infect"},{"issue":"51","key":"1243_CR66","doi-asserted-by":"publisher","first-page":"12896","DOI":"10.1073\/pnas.1721095115","volume":"115","author":"KP Klugman","year":"2018","unstructured":"Klugman KP, Black S. Impact of existing vaccines in reducing antibiotic resistance: primary and secondary effects. Proc Natl Acad Sci. 2018;115(51):12896\u2013901.","journal-title":"Proc Natl Acad Sci"},{"issue":"12","key":"1243_CR67","doi-asserted-by":"publisher","first-page":"e1176","DOI":"10.1016\/S2214-109X(17)30364-9","volume":"5","author":"AS Ginsburg","year":"2017","unstructured":"Ginsburg AS, Klugman KP. Vaccination to reduce antimicrobial resistance. Lancet Glob Health. 2017;5(12):e1176\u20137.","journal-title":"Lancet Glob Health"},{"issue":"6","key":"1243_CR68","doi-asserted-by":"publisher","first-page":"e213","DOI":"10.1016\/S1473-3099(18)30660-1","volume":"19","author":"JA Lewnard","year":"2019","unstructured":"Lewnard JA, Hanage WP. Making sense of differences in pneumococcal serotype replacement. Lancet Infect Dis. 2019;19(6):e213\u201320.","journal-title":"Lancet Infect Dis"},{"issue":"51","key":"1243_CR69","doi-asserted-by":"publisher","first-page":"12911","DOI":"10.1073\/pnas.1717161115","volume":"115","author":"JP Sevilla","year":"2018","unstructured":"Sevilla JP, Bloom DE, Cadarette D, Jit M, Lipsitch M. Toward economic evaluation of the value of vaccines and other health technologies in addressing AMR. Proc Natl Acad Sci U S A. 2018;115(51):12911\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1243_CR70","doi-asserted-by":"publisher","first-page":"05001","DOI":"10.7189\/jogh.13.05001","volume":"13","author":"R Reyburn","year":"2023","unstructured":"Reyburn R, Maher J, von Mollendorf C, et al. The impact of the introduction of ten-or thirteen-valent pneumococcal conjugate vaccines on antimicrobial-resistant pneumococcal disease and carriage: a systematic literature review. J Glob Health. 2023;13:05001.","journal-title":"J Glob Health"},{"issue":"9693","key":"1243_CR71","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/S0140-6736(09)61204-6","volume":"374","author":"KL O\u2019brien","year":"2009","unstructured":"O\u2019brien KL, Wolfson LJ, Watt JP, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5\u00a0years: global estimates. Lancet. 2009;374(9693):893\u2013902.","journal-title":"Lancet"},{"issue":"2","key":"1243_CR72","doi-asserted-by":"publisher","first-page":"81","DOI":"10.7774\/cevr.2021.10.2.81","volume":"10","author":"LM Wang","year":"2021","unstructured":"Wang LM, Hashiguchi TCO, Cecchini M. Impact of vaccination on carriage of and infection by antibiotic-resistant bacteria: a systematic review and meta-analysis. Clin Exp Vaccine Res. 2021;10(2):81.","journal-title":"Clin Exp Vaccine Res"},{"issue":"10325","key":"1243_CR73","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","volume":"399","author":"Antimicrobial Resistance Collaborators","year":"2022","unstructured":"Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629\u201355.","journal-title":"Lancet"},{"issue":"9807","key":"1243_CR74","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1016\/S0140-6736(10)62225-8","volume":"378","author":"DM Weinberger","year":"2011","unstructured":"Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet. 2011;378(9807):1962\u201373.","journal-title":"Lancet"},{"issue":"suppl_2","key":"1243_CR75","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1093\/cid\/ciu392","volume":"59","author":"B Spellberg","year":"2014","unstructured":"Spellberg B, Gilbert DN. The future of antibiotics and resistance: a tribute to a career of leadership by John Bartlett. Clin Infect Dis. 2014;59(suppl_2):S71\u20135.","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"1243_CR76","doi-asserted-by":"publisher","first-page":"S441-S","DOI":"10.1093\/ofid\/ofy210.1259","volume":"5","author":"M-C Breton","year":"2018","unstructured":"Breton M-C, Farkouh R, Vojicic J, Wilson M, McDade C, Wasserman M. 1428. Modeling reductions in antibiotic prescriptions due to otitis media in Canada as a result of pneumococcal conjugate vaccination. Open Forum Infect Dis. 2018;5(Suppl 1):S441-S.","journal-title":"Open Forum Infect Dis"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-025-01243-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-025-01243-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-025-01243-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T07:04:10Z","timestamp":1762844650000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-025-01243-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":76,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1243"],"URL":"https:\/\/doi.org\/10.1007\/s40121-025-01243-x","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]},"assertion":[{"value":"30 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mark H. Rozenbaum, Maria J. Tort, Katherine K. Perez, Benjamin M Althouse, Raymond Farkouh, and Mark Rozenbaum are employed by Pfizer Inc. and hold Pfizer stock. Ruth Chapman and Desmond Dillon-Murphy are employees of Evidera Inc., which received funding from Pfizer in connection with this study and the development of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}